Cargando…
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035792/ https://www.ncbi.nlm.nih.gov/pubmed/27502705 http://dx.doi.org/10.1093/annonc/mdw288 |